Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of oral sildenafil dose on mortality in adults with pulmonary arterial hypertension
2013-004362-34Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sildenafil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Pfizer. Primary endpoint: All-cause mortality non-inferiority (sildenafil 80 mg vs 5 mg). Started Mar 2014; status: completed.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2013-004362-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004362-34.